Internal Medicine, Hematology & Oncology · Wellington, FL
NPI
1114972254
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
8440 Lake Worth Rd Ste 200
Wellington, FL, 33467
Phone (561) 740-0545
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.5M
635,619 services
Medicare patients, 2024
704
Average age 79
Drug cost, 2024
$5.9M
2,325 prescriptions
Company payments, 2025
$6,101
From 55 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul J Lin was code J1439 (injection, ferric carboxymaltose, 1 mg), 200,250 times for 125 patients. In total Paul J Lin billed 635,619 services in 121 codes, and Medicare paid $3.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 200,250 | 125 | $0.87 | $175K |
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 154,020 | 17 | $0.27 | $41K |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 76,740 | 14 | $0.22 | $17K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 31,980 | 79 | $5.86 | $187K |
| J0897 Injection, denosumab, 1 mg | Office | 13,080 | 75 | $20.49 | $268K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 7,242 | 17 | $35.52 | $257K |
| J2796 Injection, romiplostim, 10 micrograms | Office | 4,178 | 19 | $77.90 | $325K |
| 85025 Blood Count | Office | 3,244 | 622 | $7.57 | $25K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,864 | 31 | $0.09 | $259 |
| 36415 Venipuncture Blood Collection | Office | 2,823 | 636 | $8.65 | $24K |
| 99214 Office E&M - Established | Office | 2,068 | 610 | $98.64 | $204K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,970 | 33 | $0.75 | $1,468 |
| 96372 Injection Administration | Office | 1,654 | 181 | $11.30 | $19K |
| 99213 Office E&M - Established | Office | 1,372 | 290 | $69.48 | $95K |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 1,160 | 11 | $3.65 | $4,236 |
By year: 2022 $3.3M for 633,154 services; 2023 $3.3M for 687,841 services; 2024 $3.5M for 635,619 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 3,244 | 622 | $7.57 | $25K |
| 36415 Venipuncture Blood Collection | 2,823 | 636 | $8.65 | $24K |
Medicare prescription drug claims, 2024
In 2024, the drug Paul J Lin prescribed most often to Medicare patients was Hydroxyurea, with 168 prescriptions and refills. In total Paul J Lin wrote 2,325 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxyurea Generic | 168 | 322 | 35 | $5,074 |
| Eliquis Apixaban | 160 | 263 | 33 | $153K |
| Dexamethasone Generic | 116 | 124 | 44 | $1,731 |
| Letrozole Generic | 104 | 238 | 26 | $2,157 |
| Xarelto Rivaroxaban | 78 | 132 | 21 | $72K |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | 70 | 70 | Under 11 | $412K |
| Ondansetron Hcl Generic | 66 | 70 | 45 | $539 |
| Prednisone Generic | 65 | 74 | 16 | $356 |
| Acyclovir Generic | 60 | 144 | 19 | $986 |
| Keytruda Pembrolizumab | 49 | 49 | Under 11 | $548K |
| Abiraterone Acetate Generic | 42 | 42 | Under 11 | $11K |
| Lenalidomide Generic | 40 | 40 | Under 11 | $540K |
| Gabapentin Generic | 39 | 43 | 12 | $320 |
| Xgeva Denosumab | 37 | 37 | Under 11 | $120K |
| Nystatin Generic | 36 | 41 | 13 | $555 |
Brand drugs: 829 claims; generic drugs: 1,496 claims; opioid claims: 77.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul J Lin $6,101 ($6,101 in general payments such as food, travel and fees) from 55 companies. The largest payer was Pfizer Inc. with $459.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 27 | $459 |
| Janssen Biotech, Inc. JNJ | 19 | $408 |
| Incyte Corporation INCY | 9 | $408 |
| Merck Sharp & Dohme LLC MRK | 15 | $374 |
| Daiichi Sankyo Inc. 4568.T | 16 | $370 |
| AstraZeneca Pharmaceuticals LP AZN | 16 | $357 |
| Exelixis Inc. EXEL | 16 | $286 |
| Genzyme Corporation SNY | 13 | $280 |
| GlaxoSmithKline, LLC. GSK | 14 | $273 |
| Lilly USA, LLC LLY | 10 | $218 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.